Abstracts Archive - Page 862 of 2607 - ACR Meeting Abstracts

Abstract Number: 0384 • ACR Convergence 2020
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
Nancy Wareing¹, Ning Li², Elizabeth Volkmann³, Marka Lyons⁴, Michael Roth², Donald Tashkin² and Shervin Assassi¹, ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of California, Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature. However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
Abstract Number: 0385 • ACR Convergence 2020
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis
Melody Chung¹, Antonia Maria Valenzuela Vergara², Benjamin Catanese¹, Shufeng Li¹, Kate Stevens¹ and Lorinda Chung³, ¹Stanford University, Stanford, CA, ²Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile, ³Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: Calcinosis is characterized by calcium deposition in skin and subcutaneous tissues and progresses over one year in the majority of systemic sclerosis (SSc) patients. Since…
Abstract Number: 0386 • ACR Convergence 2020
Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ Hematopoietic Stem Cells Without G-CSF
John DiPersio¹, Jonathan Hoggatt², Steven Devine³, David Scadden², Haley Howell⁴, Veit Schmelmer⁴, Glen Raffel⁴, Pat Falahee⁴, Kevin Goncalves⁴, William Savage⁴ and John Davis⁴, ¹Washington University, Saint Louis, ²Massachusetts General Hospital, Boston, ³National Marrow Donor Program, Minneapolis, ⁴Magenta Therapeutics, Cambridge
Background/Purpose: Autologous hematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with scleroderma and other autoimmune diseases. HSC transplant requires collection…
Abstract Number: 0387 • ACR Convergence 2020
Altered Iron Homeostasis and Pulmonary Haemodynamics in Systemic Sclerosis Associated Pulmonary Arterial Hypertension
Alper Sari¹, Christopher Denton², Svetlana Nihtyanova³, Benjamin Schreiber⁴ and Voon Ong³, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Iron deficiency (ID) is more frequent in systemic sclerosis (SSc) patients with pulmonary hypertension (PH) than those without and associated with worse prognosis. There…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…
Abstract Number: 0389 • ACR Convergence 2020
Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Kyle Kidwell¹, Leslie J. Crofford¹ and April Barnado¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Assembling large cohorts of patients with rare diseases is difficult and limits the power to assess outcomes in systemic sclerosis (SSc) studies. Treatment in…
Abstract Number: 0390 • ACR Convergence 2020
Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry
Flavia Castelino¹, John VanBuren², Emily Startup², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Dinesh Khanna¹², Nora Sandorfi¹³, Ami Shah¹⁴, Victoria Shanmugam¹⁵ and Virginia Steen¹⁶, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Michigan, Ann Arbor, MI, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁵The George Washington University, Washington, DC, ¹⁶Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in SSc. Several international observational studies have evaluated characteristics of ILD in their SSc patient…
Abstract Number: 0391 • ACR Convergence 2020
Defining the Optimal Disease Duration of Early Diffuse Systemic Sclerosis for Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Yuqing Zhang⁴, Robert Lafyatis⁵, Virginia Steen⁶ and Thomas Medsger⁷, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵University of Pittsburgh, Arlington, MA, ⁶Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁷University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) have historically used the modified Rodnan skin score (mRSS) as the primary outcome measure. These…
Abstract Number: 0392 • ACR Convergence 2020
Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years
Janet Pope¹, Kobina Quansah², Martin Kolb³, Jason Flavin⁴, Hassan Shazia⁵ and Soo Jin Seung⁵, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Boehringer Ingelheim (Canada) Limited, Burlington, ON, Canada, ³McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada, ⁴Boehringer Ingelheim, Corporate Headquarters, Burlington, ON, Canada, ⁵HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin thickening, vascular lesions and fibrotic changes in various organs, mainly the lungs, heart, intestinal…
Abstract Number: 0393 • ACR Convergence 2020
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)
Boyang Zheng¹, Mianbo Wang², Kerry McKenna³, Lee Shapiro⁴, Robert Spiera⁵, Richard Silver⁶, Mary Ellen Csuka⁷, Frank van den Hoogen⁸, David Robinson⁹, Laura Hummers¹⁰, Thomas Krieg¹¹, Francesco Del Galdo¹², Niall Jones¹³, Nader Khalidi¹⁴, Alessandra Vacca¹⁵, Jessica Gordon¹⁶, John Pauling¹⁷ and Murray Baron¹⁸, ¹McGill University, Montreal, Canada, ²Lady Davis institute for Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, Canada, ⁴Albany Medical College, Stillwater, NY, ⁵Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁶Medical University of South Carolina, Charleston, ⁷Medical college of Wisconsin, Milwaukee, WI, ⁸Sint Maartenskliniek, Nijmegen, Netherlands, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Johns Hopkins Univerisity, Ellicott City, MD, ¹¹University of Cologne, Cologne, Germany, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ¹³Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹⁴McMaster University, Hamilton, ON, Canada, ¹⁵University Hospital of Cagliari, Monserrato, Italy, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁸Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse cutaneous Systemic Sclerosis (dcSSc) is a morbid disease involving the skin and internal organs. The American College of Rheumatology has provisionally approved a…
Abstract Number: 0394 • ACR Convergence 2020
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
Guanying Wang¹, Diane Mar², Joy Wu³, Julia Simard⁴, Rita Popat¹ and Lorinda Chung⁵, ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Palo Alto, CA, ²Stanford Department of Immunology/Rheumatology, Palo Alto, CA, ³Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…
Abstract Number: 0395 • ACR Convergence 2020
African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis
Julia Hartman¹, Andrea Conte², Chloe Borden³, Urvashi Kaundal⁴, Yongbing Zhao², Sarah Safran⁵, Ami Shah⁶, Maureen Mayes⁷, Ayo Doumatey⁸, Amy Bentley⁹, Daniel Shriner⁸, Robyn Domsic¹⁰, Thomas Medsger¹¹, Paula Ramos¹², Richard Silver¹³, Virginia Steen¹⁴, John Varga¹⁵, Vivien Hsu¹⁶, Lesley Ann Saketkoo¹⁷, Elena Schiopu¹⁸, Dinesh Khanna¹⁹, Jessica Gordon²⁰, Lindsey Criswell²¹, Heather Gladue²², Chris Derk²³, Elana Bernstein²⁴, S. Louis Bridges²⁵, Victoria Shanmugam²⁶, Kathleen Kolstad²⁷, Lorinda Chung²⁸, Suzanne Kafaja²⁹, Reem Jan³⁰, Marcin Trojanowski³¹, Avram Goldberg³², Benjamin Korman³³, Monique Hinchcliff³⁴, Settara Chandrasekharappa⁸, Stefania Dell'Orso³, Adebowale Adeyemo⁸, Charles Rotimi⁸, Elaine Remmers³⁵, Fredrick Wigley³⁶, Daniel Kastner³⁵, Francesco Boin³⁷, Rafael Casellas² and Pravitt Gourh⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, ⁶Johns Hopkins University School of Medicine, Ellicott City, MD, ⁷University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁸National Human Genome Research Institute, Bethesda, ⁹National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, ¹⁰University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹¹University of Pittsburgh School of Medicine, Verona, PA, ¹²Medical University of South Carolina, Charleston, SC, ¹³Medical University of South Carolina, Charleston, ¹⁴Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁵Northwestern University, Chicago, IL, ¹⁶Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁷Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Hospital for Special Surgery, New York, NY, ²¹Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ²²Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Columbia University, New York, NY, ²⁵University of Alabama at Birmingham, Mountain Brk, AL, ²⁶The George Washington University, Washington, DC, ²⁷Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ²⁹David Geffen School of Medicine, UCLA, Los Angeles, CA, ³⁰Pritzker School of Medicine, University of Chicago, Chicago, IL, ³¹Boston University Medical Center, BOSTON, MA, ³²NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, ³³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³⁴Yale School of Medicine, Westport, CT, ³⁵National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ³⁶Johns Hopkins University School of Medicine, Baltimore, MD, ³⁷University of California San Francisco, Cedars-Sinai, West Hollywood, CA
Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
Abstract Number: 0396 • ACR Convergence 2020
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Daniel Furst*⁴ and Christopher Denton⁵, ¹University of Michigan, Ann Arbor, MI, ²Genentech, South San Francisco, CA, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ⁵University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-α antibody tocilizumab (TCZ) demonstrated skin score improvement and forced vital capacity (FVC) preservation in patients with systemic sclerosis (SSc) in…
Abstract Number: 0397 • ACR Convergence 2020
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease
Matthew Herrmann¹ and Zineb Aouhab¹, ¹Loyola University Medical Center, Maywood, IL
Background/Purpose: Feared complications of systemic sclerosis (SSc) affect the pulmonary system, with pulmonary hypertension and interstitial lung disease being common causes of mortality. Baseline and…
Abstract Number: 0398 • ACR Convergence 2020
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Emily Startup², Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Nora Sandorfi¹², Ami Shah¹³, Victoria Shanmugam¹⁴, Virginia Steen¹⁵ and Dinesh Khanna¹⁶, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁴The George Washington University, Washington, DC, ¹⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].